Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril-valsartan plus dapagliflozin versus RAAS inhibitors for left ventricular remodeling after acute myocardial infarction in very elderly hospitalized patients
ChiCTR2000035387Phase 4Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan and dapagliflozin in myocardial infarction (MI) (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoints: Left ventricular end diastolic diameter at 12 months, Left ventricular end systolic diameter at 12 months and 1 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
sacubitril + valsartandapagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2000035387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035387.